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In addition to its expression in stem cells and many cancers,
telomerase activity is transiently induced inmurinebleomycin (BLM)–
induced pulmonary fibrosis with increased levels of telomerase
transcriptase (TERT) expression, which is essential for fibrosis. To
extend these observations to human chronic fibrotic lung disease,
we investigated the expression of telomerase activity in lung fibro-
blasts from patients with interstitial lung diseases (ILDs), including
idiopathicpulmonaryfibrosis (IPF).The results showedthat telomer-
ase activity was induced in more than 66% of IPF lung fibroblast
samples, in comparison with less than 29% from control samples,
someofwhichwere obtained from lung cancer resections. Less than
4%of thehuman IPF lungfibroblast samples exhibited shortened telo-
meres, whereas less than 6% of peripheral blood leukocyte samples
from patients with IPF or hypersensitivity pneumonitis demonstrated
shortened telomeres. Moreover, shortened telomeres in late-
generation telomerase RNA component knockout mice did not exert
a significant effect on BLM-induced pulmonary fibrosis. In contrast,
TERT knockout mice exhibited deficient fibrosis that was independent
of telomere length. Finally, TERT expressionwas up-regulated by a his-
tone deacetylase inhibitor, while the induction of TERT in lung fibro-
blastswasassociatedwiththebindingofacetylatedhistoneH3K9tothe
TERTpromoter region.Thesefindings indicate that significant telomer-
ase inductionwas evident in fibroblasts fromfibroticmurine lungs and
a majority of IPF lung samples, whereas telomere shortening was not
a common finding in the human blood and lung fibroblast samples.
Notably, the animal studies indicated that the pathogenesis of pulmo-
nary fibrosis was independent of telomere length.
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Telomerase participates in the maintenance of telomere length
by adding TTAGGG telomeric DNA repeats onto the ends of
chromosomes de novo, while telomeres are shortened with each
round of cell division (1–3). Telomerase consists of a catalytic
reverse transcriptase (TERT) and an RNA component (TR)
that serves as a template for telomere elongation. Cells lacking
telomerase activity do not express TERT, whereas they still
express TR constitutively (4). This suggests that the limiting
factor for cellular expression of telomerase activity is TERT
gene expression.
Telomerase activity is widely expressed in cancerous cells and is
undetectable in adult somatic cells, but it is transiently induced in
various tissues undergoing injury, repair, and fibrosis. Bleomycin
(BLM), hypoxia, and silica-induced lung injury and fibrosis in
rodents are characterized by the induction of telomerase in epithe-
lial cells and fibroblasts (5–7). Our previous animal studies showed
that telomerase activity is transiently induced in BLM-treated
fibrotic lung tissue. This is accompanied by increased TERT ex-
pression, which is obligatory for the full expression of fibrosis,
because TERT deficiency impairs fibrosis along with a decreased
expression level of a–smooth muscle actin (a-SMA), a myofibro-
blast differentiation marker. Reduced fibrosis in TERT knockout
(KO) mice can be restored by transplantation with wild-type
(WT) bone marrow (BM), thus implicating the importance of
a TERT-inducible, BM-derived cell during fibrosis (5, 8–10). A
recent report revealed that fibroblast telomerase expression is
higher in areas of early remodeling in lung tissue of idiopathic
pulmonary fibrosis (IPF), which precedes the a-SMA expression
that dominates in areas of late remodeling (11).
Recent studies suggested a potential role for telomerase in
a subset of patients with a familial form of IPF that is associated
with telomere length shortening (12–16). Mutations in the
TERT and/or TR genes have been identified in some familial
cases of IPF accompanied with shortened telomeres. These
shortened telomeres are thought to constitute a predisposing
factor in the development of fibrosis upon exposure to injurious
stimulus, perhaps by an impairment of tissue repair. Some
patients with sporadic IPF exhibit telomere shortening indepen-
dent of any mutations in the TERT or TR genes, and the mech-
anism of this telomere shortening is unknown. Moreover, the
precise roles, as well as the mechanism of the genesis, of
telomerase/telomere alterations in IPF remain unclear.
The objective of the present study was to investigate whether
telomerase was also induced in human lung fibroblast (HLF) cul-
tures frompatientswith interstitial lung disease (ILD), and to eval-
uate how this could relate to telomere length in pulmonary fibrosis.
MATERIALS AND METHODS
Human Subjects
Human leukocyte DNA was extracted from 70 patients with IPF, 86
patients with hypersensitivity pneumonitis (HP), and 117 normal control
subjects. The mean ages of these three groups were not statistically sig-
nificantly different from each other (P ¼ 0.33). HLFs were isolated
from 36 patients with IPF, five patients with systemic sclerosis (SSc),
six patients with HP, three patients with idiopathic nonspecific inter-
stitial pneumonia (iNSIP), and 21 control subjects, and were maintained
in Dulbecco’s Modified Eagle’s Medium (DMEM; Life Technologies,
Carlsbad, CA) supplemented with 10% FBS (more information on hu-
man demographics, sample sources, disease diagnoses, and human study
approval is available in the online supplement).
Mice and Induction by BLM of Pulmonary Fibrosis
C57BL/6 mice were purchased from the Jackson Laboratory (Bar
Harbor, ME). TERT and TR heterozygous KO mice on a C57BL/6
(Received in original form December 13, 2012 and in final form March 13, 2013)
This research was supported by National Institutes of Health grants HL028737
(S.H.P.), HL052285 (S.H.P.), HL077297 (S.H.P.), HL074882 (C.A.H.), HL091775
(S.H.P. and C.A.H.), and AR05084 (C.A.F.-B.), and by grant PS09/00672 from the
Instituto de Salud Carlos III, Spain (A.X.).
Correspondence and requests for reprints should be addressed to Sem H. Phan,
M.D., Ph.D., Department of Pathology, University of Michigan Medical School,
109 Zina Pitcher Place, Ann Arbor, MI 48109-2200. E-mail: shphan@umich.edu
This article has an online supplement, which is accessible from this issue’s table of
contents at www.atsjournals.org
Am J Respir Cell Mol Biol Vol 49, Iss. 2, pp 260–268, Aug 2013
Copyright ª 2013 by the American Thoracic Society
Originally Published in Press as DOI: 10.1165/rcmb.2012-0514OC on March 22, 2013
Internet address: www.atsjournals.org
background were the kind gifts of Dr. Fuyuki Ishikawa (Kyoto Univer-
sity, Kyoto, Japan) and Dr. Carol Greider (Johns Hopkins University
School of Medicine, Baltimore, MD), respectively (animal study ap-
proval and more breeding details are available in the online supple-
ment). For the induction of BLM-induced pulmonary fibrosis, BLM
(Mead Johnson, Yonkers, NY) was instilled endotracheally at a dose
of 2 U/kg body weight (n ¼ 3–5 mice per group). Mouse lung fibro-
blasts (MLFs) isolated from lung tissue were maintained in DMEM
supplemented with 10% plasma-derived fetal bovine serum (PDS; An-
imal Technologies, Tyler, TX), 10 ng/ml epithelial growth factor, and
5 ng/ml platelet derived growth factor (R&D Systems, Inc., Minneapolis,
MN; more details are available in the online supplement).
Quantitative RT-PCR and Western Blotting Analysis
One-step real-time TaqMan or SYBR green–based RT-PCR was per-
formed using a GeneAmp 7500 Sequence Detection System (Applied-
Biosystems, Foster City, CA). The primer sequences are listed in the
online supplement. Western blotting to detect mouse or human TERT
(hTERT) and acetyl-H3K9 (H3K9Ac) protein expression was per-
formed with anti-mouse TERT (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA), anti-hTERT (Abcam, Cambridge, MA), anti-H3K9Ac, and
horseradish peroxidase–conjugated glyceraldehyde 3–phosphate dehy-
drogenase antibodies (Sigma, St. Louis, MO).
Telomerase Activity Assay and Telomere
Length Measurement
Telomerase activity was assayed using a telomerase PCR ELISA kit
(Roche, Indianapolis, IN) in accordance with the manufacturer’s protocol.
Cell lysates heated to 808C for 15 minutes were used as negative controls.
Telomere length was measured by terminal restriction fragment (TRF)
Southern blotting, using the Telo TAGGG Telomere Length Assay kit
(Roche). An enzyme-digested human cell DNA or MLF DNA plug was
separated on an agarose gel with regular electrophoresis for human cell
DNA, or pulsed-field electrophoresis for MLF DNA, and this was fol-
lowed by Southern blotting (more details are available in the online sup-
plement). The mean TRF was calculated as previously described (17, 18).
Chromatin Immunoprecipitation Assay
A chromatin immunoprecipitation (ChIP) assay was performed using
a ChIP assay kit (Millipore Corporation, Temecula, CA), following the
manufacturer’s protocol. Anti–acetyl-H3K9 (Sigma) was used to immu-
noprecipitate the histone–DNA complex. The PCR primers specific for
the human or mouse TERT promoter are listed in the online supplement.
Statistical Analysis
ANOVA followed by post hoc analysis using the Scheffé test was ap-
plied for comparisons between the means of various groups. A P value
of less than 0.05 was considered significant. Data are presented as
means 6 SE, unless otherwise indicated.
RESULTS
Telomerase Activity in Lung Fibroblast Cultures
from Patients with ILD
To determine whether telomerase was also induced in cells from
patients with IPF, HLFs from these and other patients with ILD
were analyzed for telomerase activity using telomerase repeat
amplification protocol (TRAP)–ELISA. The results showed
that fewer than 30% of control samples exhibited telomerase
activity (Figure 1A). In cases where control cells were isolated
from cancer resections and the distance from the tumor margins
was available, telomerase activity was found only in cells closest
to the margins. Other control samples with telomerase activity
were obtained from resections for pneumothorax or unused
lung transplant specimens. In contrast, the majority (. 60%)
of IPF and two thirds of iNSIP patient samples exhibited signif-
icant telomerase activity. Only 1 of 6 HP patient samples was
positive for telomerase activity (Figure 1A). Forty percent of the
SSc samples were also positive. The relative telomerase activities
in each disease category are shown in Figure E1 in the online
supplement. These findings suggested some association between
the induction of telomerase in HLF and fibrotic ILD.
Telomere Length Measurements in IPF and SSc Fibroblasts
Given the evidence of telomerase induction in HLF cultures
from patients with IPF, and the role of telomerase in telomere
Figure 1. Telomerase activity and telomere length analysis in lung
fibroblasts from patients with interstitial lung disease (ILD). Human
lung fibroblasts were isolated from control subjects or patients with
the indicated diagnoses. Fibroblast lysates were harvested from passage
6–10 cells. (A) Five micrograms of cell lysates were used for a telomerase
activity assay with telomerase repeat amplification protocol (TRAP)-
ELISA. The samples with absorbance at greater than or equal to 0.25,
after subtracting the absorbance reading of the negative control, were
considered positive for telomerase activity. The results are shown as
percentages of samples that were telomerase-positive in each disease
category, with the total number of samples indicated. (B) Genomic
DNA from these fibroblasts was analyzed for telomere lengths by ter-
minal restriction fragment (TRF) analysis and Southern blotting. The
results are plotted as mean telomere length. The median is indicated
with a solid line inside the shaded box, whereas the mean is indicated
with a dashed line. The lower error bar indicates the 10th percentile,
whereas the upper error bar indicates the 90th percentile. The bottom
boundary of the shaded box indicates the 25th percentile, and the upper
boundary indicates the 75th percentile. Each data point represents
results from cells from a single donor. HP, hypersensitivity pneumonitis;
IPF, idiopathic pulmonary fibrosis; NSIP, nonspecific interstitial pneu-
monia; UIP, usual interstitial pneumonia; SSc, systemic sclerosis.
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maintenance, telomere lengths in these cultures were measured
by TRF Southern blotting. The results showed that telomere
lengths were not significantly different between control, IPF,
and SSc cell samples (Figure 1B). The distribution of telomere
lengths was not significantly different between these three
groups. Only one out of the 27 (3.7%) IPF samples had a mean
telomere length below 10% of predicted, based on the control
samples. Thus, despite the induction of telomerase activity in
the cells from patients with IPF, no significant effect on telo-
mere length was evident.
Recent studies indicated shortened telomeres in some periph-
eral blood leukocyte samples from patients with sporadic and
familial IPF, involving variable associations with mutations
in TERT and/or TR genes (12–15). For comparison, genomic
DNA isolated from peripheral blood leukocytes from the Mex-
ican cohort group (70 patients with IPF, 86 patients with HP,
and 117 normal subjects) was similarly analyzed for telomere
length, and the results are shown in Figures 2A and 2B. Telo-
mere length shortening (,10% of predicted) was detected in 4
out of 70 patients with IPF (5.71%), with one other patient
manifesting borderline shortening, whereas 5.81% of patients
with HP exhibited telomere shortening, with two other patients
displaying borderline shortening. One of 117 (0.86%) control
samples displayed shortening, with an additional four exhibiting
borderline shortening. The age dependence of telomere length
was defined by the linear regression line constructed from the
control data, and the few samples from the control, IPF, and HP
groups with shortened telomeres were defined as those with
a telomere length below the 10th percentile boundary of this
regression. Thus the few cases of shortened telomeres were
identified after controlling for age on the basis of this regression
line. Smoking history did not exert a significant effect on telo-
mere length for the control (P ¼ 0.142), IPF (P ¼ 0.327), or
HP (P ¼ 0.598) groups. The proportions of shortest telomere
lengths (, 2.5 kb) were also compared between the three
groups, and the results revealed no significant differences (Fig-
ure 2C). Thus the incidence of telomere shortening in samples
from patients with IPF and HP was comparable (5.71% and
5.81%, respectively), indicating that this low frequency of telo-
mere shortening was not specific for IPF or chronic progressive
fibrotic lung disease.
Telomere Length and BLM-Induced Pulmonary Fibrosis
To assess whether telomere length was a significant factor in the
pathogenesis of pulmonary fibrosis, BLM-treated TR KO mice
were examined first for telomere shortening as a function of the
number of generations after establishing the homozygous KO of
the respective gene. TR KO MLF cultures revealed a gradual
shortening of telomeres up to the fourth generation, as reflected
by the higher amounts of shorter telomeres in blots of later gen-
erations (Figure 3A). However, the mean TRF values were not
statistically significant between the TR KO samples, but were
all significantly different from the WT samples. Notably, telo-
mere length was not affected by BLM treatment. The impact of
TR deficiency (second generation) on BLM-induced pulmonary
fibrosis was then analyzed by estimating lung collagen content,
using a biochemical assay for hydroxyproline (HYP), as previ-
ously described (18) in whole-lung homogenates on Day 21
after BLM or saline administration. The results showed that
BLM injection caused the expected increase in lung HYP con-
tent in WT mice (Figure 3B). The response to BLM in TR KO
mice was not significantly different from that in WT mice, and
this lack of effect for TR deficiency on fibrosis was also dem-
onstrated by lung collagen I mRNA concentrations that showed
responses comparable to those of BLM treatment in both WT
Figure 2. Measurement of telomere length in peripheral blood leukocytes.
Genomic DNA (1 mg) was extracted from peripheral blood leukocytes and
used for telomere length assessment. Average telomere length was measured
by performing mean TRF analysis and Southern blotting. (A) Representative
blots for IPF and control samples are shown, with the asterisk indicating a sam-
ple exhibiting a shortened telomere. “Hi” Lad, DNA ladder control with high
telomere length; “Lo” Lad, DNA ladder control with low telomere length. (B)
Telomere length was plotted versus age. The control samples (open circles)
were used to generate a regression line, with the predicted 10th and 90th
percentile indicated by the lower and upper dashed curves, respectively. The
total number of samples per group (upper right) is indicated, as well as the
percentage of samples in each group that exhibited telomere length lower
than the 10th percentile (upper left). (C) The proportions of the shortest telo-
mere signals in the three groups are shown.Mean values were not significantly
different between all three groups. The average TRF is indicated for each group.
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and TR KO mice (Figure 3C). Lung histopathology also
revealed no noticeable differences between WT and KO mice
(Figure E2). Analysis of fibrosis in third-generation and fourth-
generation TR KO mice yielded similar negative results (data
not shown), indicating that this degree of telomere shortening
exerted no significant impact on pulmonary fibrosis. TR defi-
ciency did not exert a noticeable effect on TERT expression or
its induction by BLM treatment (Figure 3D). Thus the lack of
effect for TR deficiency on fibrosis was reflected in this lack of
effect on TERT expression, previously found to be essential
for fibrosis. In contrast to this lack of effect for TR deficiency
on fibrosis, fourth-generation TERT KO mice exhibited reduced
fibrosis, which was comparable to that in second-generation KO
mice (8) as assessed by total lung HYP content (Figure 3E).
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BLM exerted a minor (15% increase above saline control sam-
ples) but statistically insignificant effect on lung HYP in fourth
generation TERT KO mice, in contrast to the significant induc-
tion (48% increase over saline control samples) in WT mice.
Although the mean value for KO BLM lungs was lower than
that in WT BLM lungs, the difference between them was not
statistically significant (P ¼ 0.16). This reduced responsiveness
to BLM in TERT KO mice was also reflected in lung collagen I
protein concentrations (Figure E3). Similar to TR KO mice,
TERT KO mice exhibited gradual telomere shortening as
a function of generation, which was not affected by BLM treat-
ment (Figure E4). Thus telomere length shortening failed to
affect reduced fibrosis significantly in TERT KO mice. Taken
together, these findings suggest that pulmonary fibrosis in this
BLM-induced model was dependent on TERT, but was inde-
pendent of changes in lung fibroblast telomere length.
Histone Acetylation in the Induction of TERT
Gene Expression
To better understand the mechanisms by which TERT expres-
sion differed in IPF from normal control samples, we investigated
histone acetylation status in TERT gene expression. Consistent
with the induction of telomerase activity, hTERT gene expres-
sion was increased in HLFs from patients with IPF relative to
those from control subjects (Figure 4A), which was significantly
correlated with H3K9Ac (R2 ¼ 0.64, P , 0.001; Figure 4B). The
correlation was substantially decreased (R2 ¼ 0.37) in control
samples alone (Figure 4C), suggesting that induced TERT ex-
pression in IPF cells may be attributable to increased H3K9
acetylation.
To evaluate this possibility, the effect of the histone deacety-
lase inhibitor, Trichostatin A (TSA), on TERT expression was
analyzed. The results showed that TSA induced TERT mRNA
expression in HLFs in a time and dose-dependent manner (Fig-
ure 5A). The TERT mRNA concentrations showed a dramatic
induction with a greater than 30-fold peak increase by 2 mM
TSA at 12 hours of treatment, and with a significant increase as
early as 4 hours. The increase in expression remained high
(i.e., a fivefold increase) at 24 hours. Consistent with mRNA
induction, TERT protein was also induced by TSA treatment at
24 hours, which was associated with an increased level of global
H3K9 acetylation (Figure 5B). A ChIP assay was performed
next to detect the specific H3K9 acetylation status at the
hTERT promoter region. The results revealed that the binding
of H3K9Ac at the hTERT promoter was 60% higher in IPF
cells with induced telomerase activity than in control cells with
undetectable telomerase activity (Figure 6A). Moreover, when
cells from patients with IPF were treated with TSA, a dose-
dependent stimulation of H3K9Ac binding at the hTERT pro-
moter resulted in a greater than 10-fold increase at a dose of
2 mM (Figure 6B). Thus the induction of TERT was associated
with the increased binding of H3K9Ac specifically at the hTERT
promoter.
The up-regulation of TERT expression by histone acetylation
was also confirmed in MLF cultures in BLM-induced pulmonary
fibrosis when the MLF cultures were treated with TSA (Figures
7A and 7B, respectively). The higher concentration of mouse
TERT (mTERT) in cells from BLM-treated mice was associ-
ated with higher concentrations of H3K9Ac (Figure 7C). As in
HLFs, increased H3K9Ac binding to the mTERT promoter was
also observed when the murine cells were treated with TSA
(data not shown). These observations, taken together, are con-
sistent with a regulatory role for histone acetylation in the in-
duction of TERT and telomerase activity in cells from lungs
undergoing fibrosis.
DISCUSSION
Tissue injury and associated repair/remodeling responses are
linked with some degree of telomerase induction. Telomerase
played an essential role in an animal model of pulmonary fibrosis
(5, 8–10). In this study, we present evidence that telomerase
activity was induced in the majority of lung fibroblast cultures
from patients with IPF, in contrast to less than 30% of control
samples, indicating some degree of specificity for fibrotic ILD.
Because the induced telomerase activity in lung fibroblasts
declines with passage number in tissue culture (10, 19), these
are likely underestimates of the actual incidence of telomerase
induction. In contrast, telomere length shortening was a low-
frequency (z 6%) event in IPF and HP, indicating that such
shortening was not specific for IPF or fibrotic ILD. These find-
ings indicated a greater association between IPF and telomerase
induction than telomere shortening. Moreover, telomere
lengths were not significantly altered in the murine BLM model
of pulmonary fibrosis, and shortened telomere lengths did not
affect fibrosis significantly in this model. These data are in
agreement with one study, in which the shortened telomere
length in TR or TERT deficiency mice did not predispose them
to enhanced BLM-induced lung fibrosis (20). In the present
study, however, TERT deficiency impaired fibrosis independent
of telomere length, whereas TR deficiency exerted no effect on
fibrosis. The basis for these discrepant results on the effect of
TERT deficiency in pulmonary fibrosis is unclear, but may be
attributable to the different TERT KO strains used in these
studies (21, 22). Nevertheless, both studies showed that telo-
mere length exerts no significant effect on pulmonary fibrosis
in this animal model. Finally, TERT activation in both IPF cells
and murine cells from the BLMmodel appeared to be regulated
by histone (H3K9) acetylation, similar to that seen in other cell
types (23, 24), indicating that the epigenetic regulation of the
TERT gene by histone acetylation may be involved in the in-
duction of telomerase during fibrotic pathogenesis.
;
Figure 3. Effects of telomerase RNA component (TR) or telomerase catalytic reverse transcriptase (TERT) deficiency on telomere length, TERT
expression, and pulmonary fibrosis. (A) Genomic DNA from lung fibroblasts were isolated from bleomycin (BLM)–treated or saline (SAL)–treated
wild-type (WT) or TR knockout (KO) mice, and analyzed for telomere length by TRF assay, followed by Southern blotting. The quantitative analysis is
shown at left (n ¼ 3, *P , 0.05), and a representative blot is shown at right. G, generation. The effect of TR deficiency on fibrosis is shown as lung
hydroxyproline content in whole-lung homogenates on Day 21 after BLM or SAL administration (B) and as procollagen I mRNA concentrations (C).
Data are presented as means 6 SEs, with n ¼ 5 animals per group. Asterisks indicate a statistically significant difference (P , 0.05) from the
corresponding SAL control groups. (D) The effect of TR deficiency on the BLM induction of TERT was analyzed. Lung-tissue lysates from WT and TR
KO mice on Day 21 after BLM or SAL treatment were analyzed for TERT protein expression by Western blotting. Representative blots are shown. The
lane on the right shows a negative control for the TERT antibody, using TERT KO lung lysate. (E) The effects of prolonged TERT deficiency on
pulmonary fibrosis were analyzed by hydroxyproline assay in SAL-treated or BLM-treated G4 TERT KO mice. Data are expressed as percentages of
respective SAL-treated groups (n ¼ 5 mice per group). An asterisk indicates a statistically significant difference (P ¼ 0.012) from the corresponding
SAL-treated control group.
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The pathogenic significance of induced telomerase activity in
cells from patients with IPF or iNSIP is unclear, but such activity
may afford survival advantages for these cells, and may thus con-
tribute to the persistence of the mesenchymal response. Telo-
merase is also known to be reactivated during tissue injury
and remodeling, in addition to its presence in germ cells and can-
cerous cells. In response to hypoxia and during hypertension,
telomerase is selectively activated in human and rat vascular
smooth muscle cells, and its down-regulation suppresses their
proliferative response (25, 26). Telomerase activity is also in-
duced in atherosclerotic coronary arteries, a finding correlated
with the induction of TERT (27). Some inflammatory stimuli,
including LPS and TNF-a, could activate telomerase and TERT
expression, via NF-kB signaling in response to LPS in macro-
phages of human atherosclerotic lesions (28). Thus telomerase
may be important in the fibroproliferative response during tis-
sue remodeling. Moreover, our findings suggest the possibility
that the induction of telomerase in lung fibroblast cultures, per-
haps obtained from lavage or transbronchial biopsy samples,
may constitute a useful biomarker for either fibrotic ILD and/
or the progression/exacerbation of disease.
Because adult somatic cells usually lack telomerase activity, the
basis for the telomerase activity in the control samples remains
unclear. Proximity to tumor margins in the control samples from
tumor resections was found to be associated with telomerase ac-
tivity, but other samples from pneumothorax resections or trauma
victims also expressed telomerase activity. However, fibroblasts
obtained from these surgical resections may proceed from areas
with pathological abnormalities. Thus, for example, a wide variety
of pulmonary and pleural histological changes is recognized in the
setting of spontaneous pneumothorax, including an epithelial, in-
flammatory, and fibrotic reaction with the up-regulation of a num-
ber of hypoxia-related, apoptosis-related, and inflammation-related
genes upon microarray analysis (29, 30).
Despite the activation of telomerase in IPF and iNSIP fibro-
blasts, the distribution of telomere lengths in these cells was not
significantly affected. Along with the dichotomy in the effect of
TERT versus TR deficiency on fibrosis, this would argue that the
significance of activation of telomerase may not be related to its
telomere maintenance function, which would not be unprece-
dented. The function of TERT in the proliferation of hair-
follicle stem cells is independent of its telomere maintenance
role (31, 32). Transgenic TERT expression in mice induces
a marked up-regulation of int/Wingless (Wnt) signaling during
the promotion of podocyte proliferation and de-differentiation
in adult kidneys (33). Interestingly, Wnt–b-catenin signaling is
implicated in the pathogenesis of IPF (34).
This activation of telomerase in lung fibroblast cultures from
patients with fibrotic ILD seems conceptually in conflict with the
suggested importance of telomere length shortening associated
with variable rate of TERT/TR mutations reported in patients
with IPF, with as many as 37% for the familial type and 25%
for sporadic cases (12, 14–16). However, one study showed no
evidence of telomere shortening (0%) in BM mesenchymal
stem cells from patients with IPF or in those with rheumatoid
arthritis–related usual interstitial pneumonia (UIP) (35). The
different estimates for the incidence of telomere shortening
;
Figure 4. Human lung fibroblast TERT expression and histone acetyla-
tion. (A) Lung fibroblasts isolated from patients with IPF and control
subjects (at passages 6–10) were analyzed for TERT protein expression
by Western blotting. Glyceraldehyde 3–phosphate dehydrogenase
(GAPDH) signals were used as a loading control. Data are expressed
as relative integration units, and are normalized as percentages of
GAPDH signals (n ¼ 7 per group). Each data point represented result
from cells from a single donor, and the significance of the bars and lines
in the box plot is as described in the legend to Figure 1B. The global
histone acetylation at H3K9 were detected by acetylated H3K9 anti-
body using Western blotting, as already described, and the correlation
between the global acetylated H3K9 and TERT concentrations in lung
fibroblasts from patients with IPF (B, n ¼ 9) or control subjects (C,
n ¼ 7) were analyzed by linear regression and the results shown in
the graph. Representative blots are shown in Figure E5 of the online
supplement.
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may reflect the different populations studied. The incidence of
shortening in the samples reported here was less than 6%,
which may reflect the different population samples studied.
The present study investigated the telomere lengths in a Mexi-
can cohort, whereas other studies reported on samples collected
in the United States or Canada (12, 36). The patients with IPF
in this study were of the sporadic type, with no genetic infor-
mation available. Only one patient with IPF (with a normal lung
fibroblast mean TRF) had a known family history, but with
genetic information unknown. The different estimates for the
incidence of telomere shortening may also be attributable to the
different methods used for telomere length measurement. Nev-
ertheless, the majority of sporadic cases with telomere shorten-
ing failed to show any mutations in their TERT or TR genes.
Indeed, one study of familial IPF failed to show any mutations
in TERT or TR (37), confirming genetic heterogeneity, and
demonstrating that telomere shortening is not always associated
with TERT/TR mutations. Readily detectable mutations of
hTERT and hTR in sporadic idiopathic interstitial pneumo-
nias (IIPs) have been rare (1–3%), but 10–23% of sporadic IIPs
involved shortened telomeres, even when mutations were not
detected (12, 16). A recent study reported that 3 of 38 familial
probands and none of 50 sporadic cases studied manifested
TERT/TR mutations. The three familial TERT mutation car-
riers exhibited shortened telomeres, but telomere lengths in all
other samples from subjects without mutations were not measured
(36). These reports indicate that a minority of cases with IPF
exhibit telomere shortening, most of which is not associated with
TERT or TR mutations. Furthermore, experimental evidence is
lacking to explain how shortened telomeres could affect the de-
velopment of fibrosis, although the impairment of tissue repair
and regeneration of alveolar epithelium may conceivably be a fac-
tor in promoting fibrosis. On the other hand, the degree of telo-
mere shortening that may be required to induce susceptibility to
the development of IPF remains unclear. Shortening above 10%
of predicted, based on normal control samples, may be sufficient,
but the information is insufficient to allow such a conclusion. A
Figure 5. Trichostatin A (TSA) induction of human TERT (hTERT) in
human lung fibroblasts. (A) Lung fibroblasts from a patient with IPF
were treated with the indicated doses of TSA for the indicated times,
and then analyzed for TERT mRNA by quantitative PCR. Untreated cells
at 4 hours were used as the calibrator for the calculation of 22DDCT.
Asterisks indicate statistically a significant difference (P, 0.01) from the
corresponding untreated control samples. Representative results are
shown from at least four separate experiments with IPF cells from indi-
vidual donors. Cells were also analyzed by Western blotting for TERT
and acetylated H3K9 (H3K9Ac) protein concentrations after 24-hour
treatment with the indicated doses of TSA. (B) Representative blots.
Figure 6. Chromatin immunoprecipitation (ChIP) assay of H3K9 acet-
ylation status at the human TERT promoter. (A) The ChIP quantitative
PCR analysis was performed in cells from human control and IPF sam-
ples, and the results are shown as means 6 SE (n ¼ 3). The asterisk
indicates a statistically significant difference (P ¼ 0.005) from control
cells. (B) The cells as already described were treated with the indicated
doses of TSA for 12 hours, and then subjected to ChIP assay. The cell
DNA immunoprecipitated by acetylated H3K9 antibody was amplified
by quantitative PCR. One tenth of the supernatant before immunopre-
cipitation was used for the DNA input control. Data are expressed as
fold changes over untreated cells. The representative result is shown
from at least three separate experiments. The inset depicts a typical gel
image of quantitative PCR products. bp, base pairs. Asterisks indicate
statistically significant differences (P , 0.02) from untreated cells.
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possibility that has not been excluded from such association stud-
ies holds that the telomere shortening noted may represent an
effect of the increased cell proliferation/turnover attributable to
active disease, rather than a causative factor for fibrosis. This is
especially germane because in most cases with telomere shorten-
ing, no mutations in TERT or TR could be identified. Moreover,
it remains unclear whether telomerase activity itself is detectable
or altered in those previous studies showing shortened telomeres
in patients with IPF.
A possible resolution of this apparent conflict may involve the
opposing significance of telomerase and/or telomere length in
epithelial versus mesenchymal cells, wherein the improved sur-
vival attributable to telomerase is beneficial in epithelial cells for
regeneration and successful repair, but is detrimental if activated
in mesenchymal cells. Thus the significance of telomerase may
have to be viewed in the context of the cell in which it is
expressed, and should not be simplistically viewed as either good
or bad in the context of IPF. This is of importance, because how it
is viewed in this context will exert consequences on how a ther-
apeutic strategy can or should be crafted to either activate or in-
hibit telomerase. To target it selectively in specific cell types to
achieve an effective therapy may be necessary.
Author disclosures are available with the text of this article at www.atsjournals.org
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